# “Mother of Cannabinoids”: The Rising Potential of CBG and CBG-A > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabigerol-anxiety-cognitive-symptoms-potential/ > **Published:** 2026-02-27T11:57:17-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:13:36-04:00 > **Clinical Summary:** Explore cannabigerol anxiety cognitive symptoms research and its emerging therapeutic potential as an alternative cannabinoid for symptom management. --- ✦ New CED Clinical Relevance#72Notable Clinical InterestEmerging findings or policy developments worth monitoring closely. ResearchAnxietyMental HealthCBD Why This MattersCBG represents a pharmacologically distinct cannabinoid with preliminary evidence for anxiety and [cognitive symptom management](https://cedclinic.com/cannabidiol-antipsychotic-effects-schizophrenia-research/), offering a potential alternative for patients with inadequate response to established CBD or THC therapies. Increased [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) into CBG formulations could expand the evidence base for personalized cannabinoid selection, though clinicians should counsel patients against unguided product switching until efficacy and safety data mature. Given CBG’s position as a biosynthetic precursor to other cannabinoids, understanding its unique pharmacology may clarify cannabinoid-specific therapeutic mechanisms and inform more targeted clinical applications. Clinical Summary Cannabigerol (CBG) and its precursor cannabigerolic acid (CBGA) represent emerging cannabinoids under investigation for potential therapeutic applications in anxiety, [cognitive function](https://cedclinic.com/reverse-cholesterol-transport-function-cannabis-users/), and oncology, though the evidence base remains preliminary compared to CBD and THC. CBGA serves as the biosynthetic precursor to THC, CBD, and other cannabinoids, positioning it as a foundational compound in [cannabis chemistry](https://cedclinic.com/cannabis-varieties-differentiation-cannabinomics/) with theoretical advantages for targeted symptom management. Current research suggests patients inadequately responsive to established CBD or THC formulations may benefit from CBG-based products, though clinical data remain limited and largely derived from preclinical studies rather than robust human trials. Given the early stage of evidence, clinicians should counsel patients to discuss any consideration of CBG products with their healthcare provider before initiating or switching therapies, particularly regarding potential drug interactions and lack of standardized dosing guidance. Patients seeking alternatives to conventional or existing [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/) should understand that while CBG shows biological promise, its clinical superiority remains unproven relative to better-characterized cannabinoids. Dr. Caplan’s Take“The research on CBG is genuinely intriguing for anxiety and certain cognitive presentations, but we’re still working from a relatively small evidence base compared to CBD and THC, so I counsel patients that this isn’t a guaranteed upgrade just because it’s novel. What matters most is whether someone has actually optimized their current regimen before chasing the next cannabinoid, because most people haven’t found their real therapeutic window yet with what we already know.” Clinical Perspective While cannabigerol (CBG) and its precursor cannabigerolic acid (CBGA) show promise in preclinical and early [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) for anxiety and cognitive symptoms, the evidence base remains substantially smaller than that for CBD or THC, and most human studies are preliminary or lacking adequate sample sizes. Patients may be attracted to CBG products as an alternative after inadequate response to established cannabinoids, but this decision should be made collaboratively with their healthcare provider rather than through self-directed product switching, as potential drug interactions, individual pharmacokinetic variation, and product quality inconsistencies are not yet well-characterized across formulations. Additionally, the lack of standardized dosing, purity verification, and long-term safety data for CBG means that clinical recommendations remain speculative at present. Given these limitations, the most practical approach is to counsel interested patients to maintain open communication about cannabis use, request evidence-based just 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+%26quot%3BMother+of+Cannabinoids%26quot%3B%3A+The+Rising+Potential+of+CBG+and+CBG-A+%26%238211%3B+Cannabis+Health+Ne...+%40drcaplan&url=https%3A%2F%2Fcannabishealthnews.co.uk%2F2026%2F02%2F27%2Fmother-of-all-cannabinoids-the-rising-potential-of-cbg-and-cbg-a)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcannabishealthnews.co.uk%2F2026%2F02%2F27%2Fmother-of-all-cannabinoids-the-rising-potential-of-cbg-and-cbg-a)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+%26quot%3BMother+of+Cannabinoids%26quot%3B%3A+The+Rising+Potential+of+CBG+and+CBG-A+%26%238211%3B+Cannabis+Health+Ne...+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fcannabishealthnews.co.uk%2F2026%2F02%2F27%2Fmother-of-all-cannabinoids-the-rising-potential-of-cbg-and-cbg-a)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://cannabishealthnews.co.uk/2026/02/27/mother-of-all-cannabinoids-the-rising-potential-of-cbg-and-cbg-a](https://cannabishealthnews.co.uk/2026/02/27/mother-of-all-cannabinoids-the-rising-potential-of-cbg-and-cbg-a) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Exploring Cannabinoids and Their Role in Patient Care – Cannabis News | NUG Magazine](https://cedclinic.com/cannabinoid-therapeutics-clinical-practice-patient-care/) An overview of various cannabinoids including CBG and their potential roles in patient care and symptom management. [Read More](https://cedclinic.com/cannabinoid-therapeutics-clinical-practice-patient-care/) [Why CBG Topicals Are Becoming One of Hemp's Fastest-Growing Categories | High Times](https://cedclinic.com/why-cbg-topicals-are-becoming-one-of-hemps-fastest-growing-categories-high-times/) Insights into the rising popularity of CBG topicals and their potential benefits in therapeutic applications. [Discover More](https://cedclinic.com/why-cbg-topicals-are-becoming-one-of-hemps-fastest-growing-categories-high-times/) [Cannabis Medical Benefits and Risks: What Research Says About Its Health Effects](https://cedclinic.com/cannabis-dosing-protocols-safe-therapeutic-use/) A balanced review of cannabis medical benefits and risks, including emerging cannabinoids like CBG. [Learn More](https://cedclinic.com/cannabis-dosing-protocols-safe-therapeutic-use/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).